Tempus AI, Inc.· TEM
🇺🇸 US · MidBroad USNASDAQ
- Price
- $47.05
- Day
- +2.17%
- Mkt Cap
- $8.24B
- 52W Range
- $40.77 – $104.32
- Volume
- 3.90M
- Beta
- 3.46
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
NEW YORK, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Julie & Holleman LLP, a nationally recognized shareholder rights firm, is investigating the proposed acquisition of Personalis, Inc. (Nasdaq: PSNL) by Tempus AI, Inc. (Nasdaq: TEM), an existing Personalis shareholder and strategic partner. For a free consultation, please visit https://julieholleman.com/personalis-inc/.
Read full article
Tempus AI's founder-CEO reduced an indirect stake by about 4% through a pre-scheduled trading plan, retaining roughly 6.5 million shares as the company pursues a major acquisition.
Read full article
Tempus AI climbs 6.6% after its second-quarter loss narrows, revenues beat estimates and 2026 sales guidance rises on diagnostics and data growth.
Read full article
Tempus AI Inc. (NASDAQ:TEM) shares are trading lower on Friday as traders digest post-earnings reset in expectations.
Read full article
While the top- and bottom-line numbers for Tempus (TEM) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read full article
Tempus AI (TEM) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.22 per share a year ago.
Read full article
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today reported financial results for the quarter ended June 30, 2026. “Q2 was another exceptional quarter for us,” said Eric Lefkofsky, Founder and CEO of Tempus. “Our strategy is working given the investments we have made in AI over the past several years are driving some of the best growth rates we have seen in our two largest businesses - Oncology Diagnostic.
Read full article
Tempus AI, Inc. (TEM) Q2 2026 Earnings Call Transcript
Read full article
Tempus AI (NASDAQ:TEM) reported second-quarter financial results Thursday after market close.
Read full article
AI's next winners may emerge from an overlooked part of the market. See how three software companies are turning proprietary expertise into a potentially powerful growth engine.
Read full article
A Small AI Company Just Took the Stage at One of the Biggest Events in Computing, and It Points to Where Drug Discovery Is Headed
Read full article
TEM heads into Q2 earnings with 21.3% expected revenue growth, strong diagnostics demand and AI deals, but near-term margin pressure remains.
Read full article